FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Zacks·3d ago
More News
Best Biotech Stocks To Follow Now - January 26th
Danaher, Moderna, Vertex Pharmaceuticals, ImmunityBio, argenex, Amicus Therapeutics, and BioNTech are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...
MarketBeat·5d ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been assigned an average recommendation of "Hold" from the fourteen analysts that are covering the firm, Marketbeat.com reports. One...
MarketBeat·6d ago
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus...
Business Wire·8d ago
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Zacks·8d ago
Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 75,000 Shares
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average...
MarketBeat·8d ago
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an...
MarketBeat·9d ago
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.
Zacks·9d ago
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
Zacks·10d ago
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.